Commercializing a breakthrough advance in inflammation science. MORE
Antibe Therapeutics is a publicly traded biotechnology company exploiting groundbreaking advances in inflammation science.
Antibe Therapeutics to Host Conference Call to Discuss Positive Results of Phase 2B Dose-Ranging, Efficacy Study for ATB-346
Antibe Therapeutics Announces Positive Top-Line Data from Phase 2B Dose-Ranging, Efficacy Study for ATB-346
Antibe Therapeutics Updates Timing for Top-Line Results From Completed Phase 2B Dose-Ranging, Efficacy Study
Antibe Therapeutics Announces Enrollment of Last Patient in Phase 2B Dose-Ranging, Efficacy Study of Lead Drug, ATB-346
Antibe Therapeutics Provides Corporate Update and Reports Q3 2020 Interim Financial and Operating Results
Antibe Therapeutics Announces Research Publication Demonstrating Markedly Enhanced Pain Relief and Increased Safety of Second Pipeline Drug